Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Glioma 1Carcinosarcoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Sorafenib 37Nivolumab 21pembrolizumab 18Bevacizumab 12Cyclophosphamide 10durvalumab 9fludarabine 8atezolizumab 8Magnetic Resonance Spectroscopy 8lenvatinib 7Radiosurgery 7Ipilimumab 7Radiotherapy 6Irinotecan 6Oxaliplatin 5Leucovorin 5tremelimumab 4toripalimab 4tislelizumab 4sintilimab 4cabozantinib 4budigalimab 4Specimen Handling 4Sirolimus 4Interleukin-2 4Fluorouracil 4Doxorubicin 4Capecitabine 4130-nm albumin-bound paclitaxel 4spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Hepatocellular × LY-2157299 × Clear all
NCT02240433 2020-02-05

A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)

Eli Lilly and Company

Phase 1 Completed
9 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡